Themis Medicare consolidated PAT falls 21.05% in Q4 FY24
Themis Medicare reported a decline in consolidated net profit of 21.05% to 6.64 crore rupees in Q4 FY24 compared to 8.41 crore rupees during the corresponding quarter ending March 2023.
Key Takeaways from Themis Medicare’s Performance:
- Consolidated net profit fell 21.05% to 6.64 crore rupees in Q4 FY24.
- Total sales for the quarter stood at 97.82 crore rupees up 22.12%.
- BoD recommended a final dividend of Rs 0.5 per equity share.
Total revenue from operations stood at 97.82 crore rupees up 22.12% in the quarter ended March 2024 as against 80.10 crore rupees in the previous quarter ended March 2023.
Consolidated net profit for the full year fell 23.51% to 43.52 crore rupees in the year ending March 2024 against 56.90 crore rupees during the previous year ended March 2023. However, total sales rose 7.74% to 381.76 crore rupees in the year ended March 2024 against 354.32 crore rupees in the previous year ended March 2023.
Further, Themis Medicare announced that the board of the company at its meeting held on Tuesday recommended the final dividend of Rs 0.5 per equity share, subject to shareholders’ approval.
About Themis Medicare Limited:
Themis Medicare Limited was established in 1969 as a joint venture partnership at Vapi. Currently, it is one of the fastest-growing pharma companies specialising in the development of complex molecules. The Company has a diversified business model with a presence across the B2B model and a strong presence in the domestic B2C market. It also has a significant export presence in the RoW geographies.
